Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 12:45 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 1,851 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Deformity; Skin Clear all

Conditions: MPS I, MPS IV A, MPS - Mucopolysaccharidosis, MPS IVA
Interventions: Not listed
Lead sponsor: Children's Hospital of Orange County; Other
Eligibility: 0 Years to 99 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Orange, California • Minneapolis, Minnesota • St Louis, Missouri

Conditions: Atopic Dermatitis (AD), Psoriasis (PsO)
Interventions: LPX-TI641, Placebo; Drug
Lead sponsor: LAPIX Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Fargo, North Dakota • Dallas, Texas

Conditions: Lipodystrophy, HIV Infection
Interventions: Metformin, Pioglitazone; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fabry Disease
Interventions: Not listed
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hunter Syndrome
Interventions: No treatment; Other
Lead sponsor: Shire; Industry
Eligibility: Up to 70 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Decatur, Georgia • Chicago, Illinois • Minneapolis, Minnesota + 2 more

Conditions: Pachyonychia Congenita
Interventions: PTX-022, Placebo; Drug
Lead sponsor: Palvella Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 6 more

Conditions: Mucopolysaccharidoses
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 3 Years to 18 Years
Enrollment: 1,147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Orange, California • Minneapolis, Minnesota

Conditions: Laryngomalacia, Acid Reflux, Stridor
Interventions: ranitidine or famotidine, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: Up to 4 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Congenital Ichthyosis
Interventions: Isotretinoin, Vehicle; Drug · Other
Lead sponsor: LEO Pharma; Industry
Eligibility: 9 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 5 more

Conditions: Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Interventions: Placebo, DISC-1459; Drug
Lead sponsor: Disc Medicine, Inc; Industry
Eligibility: 12 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 11
States / cities: Huntington Beach, California • San Francisco, California • Miami, Florida + 7 more

Conditions: Healthy Volunteers
Interventions: Nemolizumab; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Atopic Dermatitis, Eczema, DNA
Interventions: DNA reports, Information reports; Behavioral
Lead sponsor: Studies&Me; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 9
States / cities: Anaheim, California • Encino, California • Miami, Florida + 6 more

Conditions: Cancer
Interventions: aprepitant, dexamethasone, ondansetron, placebo; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Mucopolysaccharidosis III
Interventions: anakinra; Biological
Lead sponsor: Lynda E Polgreen; Other
Eligibility: 4 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Torrance, California

Conditions: Mucopolysaccharidosis Type IIIB, MPS IIIB (Sanfilippo B Syndrome)
Interventions: Tralesinidase alfa (TA); Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 12 Months and older
U.S. locations: 1
States / cities: Oakland, California

Conditions: Diabetic Foot Ulcers, Equinus Deformity
Interventions: Not listed
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Atopic Dermatitis
Interventions: Abrocitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 11
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more

Conditions: Wrinkle, Fine Lines, Crepey Skin, Acne Scars, Active Acne, Enlarged Pores, Stretch Mark, Loose Skin
Interventions: RadioFrequency Microneedling Device; Device
Lead sponsor: Cynosure, Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Westford, Massachusetts

Conditions: Candidiasis, Chronic Mucocutaneous
Interventions: Amphotericin B; Drug
Lead sponsor: Matinas BioPharma Nanotechnologies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hair Loss, Skin Laxity, Cosmetic Acne, Nails; Soft, Skin Aging
Interventions: Vegetarian Collagen, Keratin, Ceramides, Astaxanthin; Dietary Supplement
Lead sponsor: ProofPilot; Industry
Eligibility: 26 Years to 100 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Short Stature
Interventions: Vosoritide; Drug
Lead sponsor: Andrew Dauber; Other
Eligibility: 3 Years to 10 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2035
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Atopic Dermatitis, Atopic Eczema, Infantile Eczema, Hand Eczema
Interventions: Patient Educational Materials; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma
Interventions: interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Cardiac Structure and Function in MPS

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

Metabolic Abnormalities in HIV-infected Persons

Androgenetic Alopecia in Fabry Disease

Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe

Using a Telemedicine Approach in a Genome-wide Association Study of Atopic Dermatitis - Searching for Novel Biomarkers in Clinically Relevant Phenotypes

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Open-label Study of Anakinra in MPS III

Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)

Determination of the Pathophysicologic Collagen Changes in the Diabetic Achilles Tendon

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for Electrocoagulation and Hemostasis of Soft Tissues for Dermatologic Conditions

CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

Nourishing Hair, Skin & Nails Supplement Study (Derm Aid)

Vosoritide for Selected Genetic Causes of Short Stature

Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis

Vaccine Therapy in Treating Patients With Metastatic Cancer